NCT05137860 2022-01-18
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Hospital General de Mexico
Phase 4 Unknown
Clinical Trials
10 trialsNCT01965977 2020-10-23
Borma
Samsung Medical Center
Phase 2 Unknown
NCT03390387 2020-02-05
ALL-MB 2015
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase NA Unknown
NCT04061772 2019-08-20
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT02542111 2017-11-14
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT03335098 2017-11-07
BOMB-THROW
Seoul National University Hospital
Phase 2 Unknown
NCT01439750 2017-08-07
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Milton S. Hershey Medical Center
Phase 1 Unknown
NCT01449344 2017-03-07
(R-HAD)
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT03016988 2017-01-11
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
Fujian Medical University
Phase 2 Unknown
NCT00261612 2006-10-18
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
Medical University of Vienna
Phase 2 Unknown